$Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.$

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

UNLABELLED: Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar spine (but not total hip) and decreased bone turnover. However, the fracture rate in these patients remained...

Full description

Bibliographic Details
Main Authors:	Bradbury, L, Barlow, S, Geoghegan, F, Hannon, R, Stuckey, S, Wass, J, Russell, R, Brown, M, Duncan, E
Format:	Journal article
Language:	English
Published:	2012

Similar Items

The ROSI study (risedronate in adults with osteogenesis imperfecta type 1)
by: Duncan, E, et al.
Published: (2005)

The ROSI study (Risedronate in adults with osteogenesis imperfecta type 1): Improved BMD but high fracture rate persists.
by: Bradbury, L, et al.
Published: (2006)

Calcitonin in osteogenesis imperfecta.
by: Smith, R, et al.
Published: (1973)

Cardiovascular abnormalities in osteogenesis imperfecta.
by: White, N, et al.
Published: (1983)

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
by: Watts, N, et al.
Published: (2004)

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
by: Watts, N, et al.
Published: (2004)

Molecular and Mesoscale Mechanisms of Osteogenesis Imperfecta Disease
by: Uzel, Sebastien Guy Marcel, et al.
Published: (2011)

Hospital admissions of patients with osteogenesis imperfecta in the English NHS
by: Kolovos, S, et al.
Published: (2021)

Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice.
by: Guillot, P, et al.
Published: (2008)

Molecular and Mesoscale Mechanisms of Osteogenesis Imperfecta Disease in Collagen Fibrils
by: Gautieri, Alfonso, et al.
Published: (2015)

Description of hospital use by patients with osteogenesis imperfecta in the English NHS
by: Kolovos, S, et al.
Published: (2020)

Conceptualization and validation of a health economic model for osteogenesis imperfecta
by: Edmonds, T, et al.
Published: (2024)

EFFECT OF BONE-MATRIX CONSTITUENTS ON OSTEOGENESIS
by: Green, E, et al.
Published: (1984)

CONSISTENT LINKAGE OF DOMINANTLY INHERITED OSTEOGENESIS IMPERFECTA TO COLLAGEN-1 GENES
by: Sykes, B, et al.
Published: (1988)

Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.
by: Jones, G, et al.
Published: (2014)

Structure–mechanics relationships of collagen fibrils in the osteogenesis imperfecta mouse model
by: Andriotis, O. G., et al.
Published: (2016)

Valuation of lost productivity of adults with X-linked Hypophosphataemia and Osteogenesis imperfecta
by: Cole, S, et al.
Published: (2023)

Osteogenesis imperfecta is linked to both type I collagen structural genes.
by: Sykes, B, et al.
Published: (1986)

Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers
by: Edmonds, T, et al.
Published: (2024)

Osteogenesis: bone development from primitive progenitors.
by: Triffitt, J, et al.
Published: (1998)

Markers of bone turnover and disease status in prostate cancer
by: Hannon, R, et al.
Published: (2003)

RISEDRONATE REDUCES MICRO-STRUCTURAL DETERIORATION OF CORTICAL BONE ACCOMPANYING MENOPAUSE
by: Seeman, E, et al.
Published: (2010)

Site and gender specificity of inheritance of bone mineral density.
by: Duncan, E, et al.
Published: (2003)

Effects of Risedronate and alendronate on colonic inflammation and bone loss in a mouse model of acute colitis
by: Brounais-Le Royer, B, et al.
Published: (2012)

Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.
by: Sugiyama, T, et al.
Published: (2011)

Valuation of lost productivity for people with osteogenesis imperfecta: preliminary results from the RUDY cohort
by: Cole, SE, et al.
Published: (2022)

Decreased bone hardness in hip fracture: Regional changes and the association with bone remodelling
by: Loveridge, N, et al.
Published: (2003)

TYPE-I COLLAGEN STRUCTURAL GENES IN OSTEOGENESIS IMPERFECTA AND OTHER HERITABLE DISORDERS OF CONNECTIVE-TISSUE
by: Wordsworth, B, et al.
Published: (1987)

Lethal osteogenesis imperfecta and a collagen gene deletion. Length polymorphism provides an alternative explanation.
by: Sykes, B, et al.
Published: (1985)

Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: a health economic modelling study
by: Edmonds, T, et al.
Published: (2024)

Physical function in UK adults with osteogenesis imperfecta: a cross-sectional analysis of the RUDY study
by: Orlando, G, et al.
Published: (2020)

PTHR1 polymorphisms and their role in variation in bone mineral density
by: Vilarino-Guell, C, et al.
Published: (2005)

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
by: Blumsohn, A, et al.
Published: (2011)

Use of radiographic densitometry to predict the bone healing index in distraction osteogenesis
by: Saw, A., et al.
Published: (2008)

Biodegradable magnesium alloys promote angio-osteogenesis to enhance bone repair
by: Han, H-S, et al.
Published: (2020)

Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures.
by: Oreffo, R, et al.
Published: (1997)

Whole Exome Sequencing is a Sensitive and Cost-Effective Means of Detecting Mutations in Patients with Marfan Syndrome and Osteogenesis Imperfecta
by: Duncan, E, et al.
Published: (2013)

Four patients with Sillence type I osteogenesis imperfecta and mild bone fragility, complicated by left ventricular cardiac valvular disease and cardiac tissue fragility caused by type I collagen mutations.
by: Vandersteen, A, et al.
Published: (2014)

Four patients with Sillence type I osteogenesis imperfecta and mild bone fragility, complicated by left ventricular cardiac valvular disease and cardiac tissue fragility caused by type I collagen mutations
by: Vandersteen, A, et al.
Published: (2013)

Bone mineral density in adults with Marfan syndrome.
by: Carter, N, et al.
Published: (2000)